Cormorant Asset Management, LP
"13F equity value" = market value of this filer's US-listed long equity positions only. It excludes cash, bonds, non-US and short positions, so it understates a fund's true assets under management — often by a lot.
13F holdings are disclosed ~45 days after quarter-end, and they never reveal when within the quarter a fund actually bought. So any 13F-based summary is structurally late and blurred — this applies to every fund, including this one.
We backtested copying it anyway. Buying this fund's new positions the day each filing went public, over 27 quarters, returned +1.8% per quarter — versus +1.8% per quarter from simply owning every 13F stock. It beat that baseline in only 40.7% of quarters (excess t = 0.66, not statistically significant). Its filings tell you what it bought — not what you should buy.
Quarterly compounding, invested quarters only · entry 47 days after quarter-end (when 13F data becomes public)
Top 20 holdings of 46 · 2026 Q1
| Ticker | Value | Weight | QoQ |
|---|---|---|---|
| PRAX | $285M | | TRIM |
| BBOT | $160M | | HOLD |
| EYPT | $107M | | HOLD |
| EWTX | $103M | | HOLD |
| ERAS | $94M | | NEW |
| RAPP | $93M | | TRIM |
| ALMS | $87M | | ADD |
| ABVX | $85M | | TRIM |
| MLTX | $84M | | ADD |
| DNTH | $80M | | NEW |
| DRUG | $77M | | HOLD |
| BBIO | $63M | | TRIM |
| OLMA | $58M | | ADD |
| BIOA | $51M | | ADD |
| CNTA | $42M | | TRIM |
| DMRA | $39M | | NEW |
| MBX | $33M | | HOLD |
| INSM | $31M | | TRIM |
| NAMS | $30M | | TRIM |
| TNGX | $30M | | NEW |
QoQ vs previous quarter's share count · NEW = new position · ADD/TRIM = ±2% shares · HOLD = unchanged.
New positions in 2026 Q1
Method & Limitations
Method: a "new position" = held this quarter, absent last quarter (options excluded; stocks with <50 prior holders excluded to filter spin-off artifacts). Entry 47 days after quarter-end — the first day the public could act on the filing. Benchmark = equal-weighted universe of all 13F-held stocks. Limitations: quarterly snapshots can't see intra-quarter trades; survivorship bias — funds that shut down are absent, which flatters the sample. Statistics, not advice.